Work

Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies

Year: 2019

Type: article

Study design: Clinical Trial

Source: Lung Cancer

DOI: 10.1016/j.lungcan.2019.09.015

Authors: Jessica A. Hellyer, Matthew A. Gubens, Kristen M. Cunanan, Sukhmani K. Padda, Matthew Burns, A. John Spittler, Jonathan W. Riess, Melanie San Pedro-Salcedo, Kavitha J. Ramchandran, Joel W. Neal, Heather A. Wakelee, Patrick J. Loehrer

Institutions: Stanford Medicine, Stanford Cancer Institute, Stanford University, University of California, San Francisco, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, UC Davis Comprehensive Cancer Center

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Clinical Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Celgene

OpenAlex ID: W2973933756

FWCI: 1.505

Cites: 18

Cited by: 21

Related to: 10